CEO Brett P. Monia received total compensation of approximately $13.4 million, which is within a reasonable range for a biotech CEO at a $12.2 billion company given Ionis's strong performance — the stock returned over +100% over three years, significantly outperforming the XBI benchmark. The prior year say-on-pay vote received approximately 96% support, signaling broad shareholder satisfaction, and the company has made meaningful improvements including increasing performance stock awards from 33% to 40% of the CEO's total equity mix and raising the bar for maximum payout to the 90th percentile of relative total shareholder return. Pay mix is appropriately weighted toward variable compensation (approximately 60% performance-based for the CEO), with a functioning clawback policy and no hedging or pledging permitted.

Non-audit fees (approximately $723,000 including $606,000 audit-related fees, $110,000 tax fees, and $7,000 other fees) represent roughly 25% of audit fees (approximately $2,890,000 including the core audit and corporate transaction fees), well below the 50% threshold that would trigger an against vote; although Ernst & Young's tenure of 37 years since 1989 exceeds the 25-year threshold, the proxy discloses a pre-approval policy and active audit committee oversight, and the policy directs a FOR vote unless the tenure trigger is the sole concern without mitigating context — here the clean fee ratio and no restatements support ratification.